The PKC inhibitor AEB071 may be a therapeutic option for psoriasis - Skvara, Hans; Dawid, Markus; Kleyn, Elise; Wolff, Barbara; Meingassner, Josef G.; Knight, Hilary; Dumortier, Thomas; Kopp, Tamara; Fallahi, Nasanin; Stary, Georg; Burkhart, Christoph; Grenet, Olivier; et al. (The Journal of clinical investigation, 2008)
Keywords: Animals; Antigens; Autoimmune diseases; Biomedical research; Care and treatment; Cell growth; Cytokines; Dendritic cells; Dermatitis; Dermatitis - drug therapy; Diagnosis; Dose-Response Relationship, Drug; Double-Blind Method; Health aspects; Humans; Hypersensitivity - drug therapy; Interleukin-2 - biosynthesis; Kinases; Lymphocyte Activation - drug effects; Lymphocytes; Lymphocytes - drug effects; Physiological aspects; Placebos; Protein Isoforms; Protein Kinase Inhibitors - pharmacokinetics; Protein Kinase Inhibitors - therapeutic use; Protein kinases; Psoriasis; Psoriasis - drug therapy; Rats; Skin - drug effects; United States